Evelyn Williams

Evelyn Williams

Auto-generated profile, based on publicly available information

Evelyn Williams

Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology 3 , Atlanta, Georgia 30332

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2025 in APL Bioengineering
Verified
Journal Article
Open access
HVHannah Viola
Hannah Viola
LCLiang-Hsin Chen
Liang-Hsin Chen
SJSeongbin Jo
Seongbin Jo
KWKendra Washington
Kendra Washington
CSCauviya Selva
Cauviya Selva
STShuichi Takayama
Shuichi Takayama
Dysregulated neutrophil recruitment drives many pulmonary diseases, but most preclinical screening methods are unsuited to evaluate pulmonary neutrophilia, limiting progress toward therapeutics. Namely, high-throughput therapeutic assays typically exclude critical neutrophilic pathophysiology, including blood-to-lung recruitment, dysfunctional activation, and resulting impacts on the air-blood barrier. To meet the conflicting demands of physiological complexity and high throughput, we developed an assay of 96-well leukocyte recruitment in an air-blood barrier array (L-ABBA-96) that enables in vivo-like neutrophil recruitment compatible with downstream phenotyping by automated flow cytometry. We modeled acute respiratory distress syndrome (ARDS) with neutrophil recruitment to 20 ng/mL epithelial-side interleukin 8 and found a dose-dependent reduction in recruitment with physiologic doses of baricitinib, a JAK1/2 inhibitor recently Food and Drug Administration-approved for severe Coronavirus Disease 2019 ARDS. Additionally, neutrophil recruitment to patient-derived cystic fibrosis sputum supernatant induced disease-mimetic recruitment and activation of healthy donor neutrophils and upregulated endothelial e-selectin. Compared to 24-well assays, the L-ABBA-96 reduces required patient sample volumes by 25 times per well and quadruples throughput per plate. Compared to microfluidic assays, the L-ABBA-96 recruits two orders of magnitude more neutrophils per well, enabling downstream flow cytometry and other standard biochemical assays. This novel pairing of high-throughput in vitro modeling of organ-level lung function with parallel high-throughput leukocyte phenotyping substantially advances opportunities for pathophysiological studies, personalized medicine, and drug testing applications.

4 April 2024 in American Journal of Hematology
Verified
Journal Article
Closed access
JMJamie O. Musick
Jamie O. Musick
EWEvelyn K. Williams
Evelyn K. Williams
KFKirby S. Fibben
Kirby S. Fibben
DZDan Y. Zhang
Dan Y. Zhang
CCChristina Caruso
Christina Caruso
WLWilbur Lam
Wilbur Lam

22 September 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
JKJames M Kelvin
James M Kelvin
DZDan Y Zhang
Dan Y Zhang
EWEvelyn K Williams
Evelyn K Williams
SMSamuel G Moore
Samuel G Moore
LBLacey A Birnbaum
Lacey A Birnbaum
EDErik C Dreaden
Erik C Dreaden
Advances in multiagent chemotherapy have led to recent improvements in overall survival for patients with acute lymphoblastic leukemia (ALL); however, a significant fraction do not respond to frontline chemotherapy or later relapse with recurrent disease, after which long-term survival rates remain low. To address the challenge of developing new, effective treatment options for these patients, we conducted a series of high-throughput combination drug screens to identify chemotherapies that synergize in a lineage-specific manner with MRX-2843, a small molecule dual MERTK and FLT3 kinase inhibitor currently in clinical testing for treatment of relapsed/refractory leukemias and solid tumors. Using experimental and computational approaches, we found that MRX-2843 synergized strongly – and in a ratio-dependent manner – with vincristine chemotherapy to inhibit T-ALL cell expansion and, based on these findings, we developed multiagent lipid nanoparticle formulations of these drugs that not only constitutively maintained ratiometric drug synergy following T-ALL cell delivery, but also improved anti-leukemic activity following drug encapsulation. To determine the clinical relevance of these combination drug formulations and the therapeutic impact of ratiometric drug synergy, we compared the efficacy of lipid nanoparticles comprising synergistic, additive, and antagonistic ratios of MRX-2843 and vincristine, and observed that trends in in vitro synergy were directly recapitulated in primary T-ALL patient samples. Together, these findings present a systematic approach to high-throughput combination drug screening and multiagent drug delivery that maximizes the therapeutic potential of combined MRX-2843 and vincristine in T-ALL. This broadly generalizable approach could lead to the development of constitutively synergistic combination products for the treatment of cancer and other diseases.

23 October 2026 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
EWE. Kendall Williams
E. Kendall Williams
DZDan Y. Zhang
Dan Y. Zhang
TATheodora T. Alese
Theodora T. Alese
RSRyan Summers
Ryan Summers
JMJamie O. Musick
Jamie O. Musick
WLWilbur Lam
Wilbur Lam

14 May 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
HVHannah Viola
Hannah Viola
LCLiang-Hsin Chen
Liang-Hsin Chen
SJSeongbin Jo
Seongbin Jo
KWKendra Washington
Kendra Washington
CSCauviya Selva
Cauviya Selva
STShuichi Takayama
Shuichi Takayama
Dysregulated neutrophil recruitment drives many pulmonary diseases, but most preclinical screening methods are unsuited to evaluate pulmonary neutrophilia, limiting progress towards therapeutics. Namely, high throughput therapeutic screening systems typically exclude critical neutrophilic pathophysiology, including blood-to-lung recruitment, dysfunctional activation, and resulting impacts on the air-blood barrier. To meet the conflicting demands of physiological complexity and high throughput, we developed an assay of 96-well Leukocyte recruitment in an Air-Blood Barrier Array (L-ABBA-96) that enables in vivo -like neutrophil recruitment compatible with downstream phenotyping by automated flow cytometry. We modeled acute respiratory distress syndrome (ARDS) with neutrophil recruitment to 20 ng/mL epithelial-side interleukin 8 (IL-8) and found a dose dependent reduction in recruitment with physiologic doses of baricitinib, a JAK1/2 inhibitor recently FDA-approved for severe COVID-19 ARDS. Additionally, neutrophil recruitment to patient-derived cystic fibrosis sputum supernatant induced disease-mimetic recruitment and activation of healthy donor neutrophils and upregulated endothelial e-selectin. Compared to 24-well assays, the L-ABBA-96 reduces required patient sample volumes by 25 times per well and quadruples throughput per plate. Compared to microfluidic assays, the L-ABBA-96 recruits two orders of magnitude more neutrophils per well, enabling downstream flow cytometry and other standard biochemical assays. This novel pairing of high-throughput in vitro modeling of organ-level lung function with parallel high-throughput leukocyte phenotyping substantially advances opportunities for pathophysiological studies, personalized medicine, and drug testing applications.